Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain

November 8, 2023
Eisai saw its operating profit zoom nearly 500% year over year in the first half of FY2023 as it enjoyed robust performances from core products and a one-time divestment gain associated with the breast cancer med elacestrant. In April-September, the...read more